<DOC>
	<DOCNO>NCT00549120</DOCNO>
	<brief_summary>Optimising propranolol block model</brief_summary>
	<brief_title>Optimising Propranolol Block Model</brief_title>
	<detailed_description>The bronchodilatory effect inhale beta2 agonist anti-muscarinic drug mainstay symptomatic treatment asthma Chronic Obstructive Pulmonary Disease ( COPD ) . A new approach combine pharmacological approach single molecule - ie dual pharmacophore . It necessary explore relative contribution beta2 agonist versus anti-muscarinic bronchodilator property molecule . One way block one component . Inhibition beta2 agonist-mediated bronchodilatation non-selective beta-blocker propranolol establish experimental method . Therefore method may useful explore pharmacology dual pharmacophore . Published study generally look effect single dose propranolol beta2 agonist relatively short period time ( hour ) . There desire develop long acting bronchodilator require daily dosing . Thus dual pharmacophore develop likely 24 hour duration action single dose . Therefore use method beta blockade inhibit beta2 agonist mediate bronchodilation , necessary confirm dose regimen propranolol acceptable tolerability effective blocking effect beta2 agonist 24 hour . That main purpose study . It also important confirm bronchodilator effect antimuscarinic unaffected beta blockade . In addition , interest examine bronchodilator effect combination antimuscarinic beta2 agonist healthy volunteer effect propranolol combination .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Healthy adult male female age 18 50 year . Body mass index within range 1929.9 kilograms/metre2 Forced Expiratory Volume 1 second ( FEV1 ) &gt; 80 % predict FEV1/ Forced Vital Capacity ( FVC ) ratio &gt; 0.7 The subject increase sGAW &gt; % predose baseline within 2 h administration 400 ug salbutamol MDI inhaler screen 3 month screen . Subject increase sGaw 25 % predose baseline within 2 h follow 40 ug ipratropium bromide screen 3 month screen Subjects current nonsmoker use tobacco product 6month period precede screen visit pack history &lt; 10 pack year . Exclusion criterion : A past present disease , judge Investigator medical monitor may affect outcome study safety subject History respiratory disease Significant abnormal 12 lead ECG , QTc ( B ) QTc ( F ) value screen &gt; 450msec individual ECG PR interval outside range 120210 msec Supine mean heart rate outside range 4590 beat per minute ( bpm ) screen Subject donate unit blood within 56 day intend donate within 56 day complete study Subject currently take regular ( course ) medication whether prescribed ( exception contraceptive , include vitamin herbal remedy St John 's Wort ) Subject participate clinical study New Chemical Entity ( NCE ) within past 1 month Infected Hepatitis B , Hepatitis C , HIV virus Subject history drug allergy , , opinion Investigator , contraindicate participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Healthy Subjects</keyword>
	<keyword>muscarinic receptor antagonist</keyword>
	<keyword>propranolol</keyword>
	<keyword>beta-blocker</keyword>
	<keyword>beta-agonist</keyword>
</DOC>